Live

FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteran Endpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027 PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseases FierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec BioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter CellSingle-cell mapping of regulatory DNA-protein interactions CellPlasma signals of lung tumor promotion for molecular cancer prevention CellDeep learning of functional perturbations from condensate morphology FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

Cell 17. Jan. 2026

Multimodal supramolecular targeting chimeras enable spatiotemporally resolved protein degradation <em>in vivo</em>

Multimodal supramolecular targeting chimeras enable spatiotemporally resolved protein degradation in vivo

Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.